High Cholesterol Clinical Trials

Find High Cholesterol Clinical Trials Near You

Effects of an Adapted Brazilian Cardioprotective Diet Supplemented or Not With Phytosterols and/or Krill Oil in Patients With Familial Hypercholesterolemia: the DICA-FH Randomized Clinical Trial

Status: Recruiting
Location: See all (24) locations...
Intervention Type: Other, Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The main objective of this randomized clinical trial is to evaluate the effects of the adapted Brazilian Cardioprotective Diet (DICA Br) supplemented or not with phytosterols and/or krill oil in patients with a probable or definitive diagnosis of familial hypercholesterolemia (FH) according to the the Dutch Lipid Clinic Network (Dutch MEDPED) criteria. In addition, the following will be considered secondary objectives: to perform participants´ whole genome sequencing (WGS); to evaluate the effects of the interventions on lipid profile biomarkers; to evaluate the frequency of mild, moderate and severe adverse events according to study groups; and to evaluate adherence rates according to study groups. In this study, 300 individuals will be randomly enrolled into four groups: 1) DICA Br adapted to the FH context (DICA-FH) + phytosterol placebo + krill oil placebo (control group); 2) DICA-FH + 2g/day of phytosterol + krill oil placebo; 3) DICA-FH + phytosterol placebo + 2g/day of krill oil; and 4) DICA-FH + 2g/day of phytosterol + 2g/day of krill oil. Primary outcomes will be LDL-cholesterol for groups phytosterol vs. placebo and lipoprotein(a) for groups krill oil vs. placebo after 120 days of follow up.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Healthy Volunteers: f
View:

• Age ≥16 years;

• Definitive (certainty) or probable diagnosis of FH by the Dutch MEDPED criteria;

• Using one of the following treatment regimens for ≥6 weeks according to age:

⁃ \>= 20 years -\> simvastatin 40 mg; lovastatin 40 mg; pravastatin 80 mg; atorvastatin 20 mg; rosuvastatin 10 mg; pitavastatin 4 mg; fluvastatin 80 mg; atorvastatin 40- 80 mg; rosuvastatin 20 - 40 mg; atorvastatin 40 - 80 mg + ezetimibe 10mg; rosuvastatin 20 - 40 mg + ezetimibe 10mg; or simvastatin 40mg + ezetimibe 10mg.

⁃ 16 to 19 years -\> simvastatin 10 - 40 mg; lovastatin 10 - 40 mg; pravastatin 10 - 40 mg; atorvastatin 10 - 40 mg; rosuvastatin 5 - 40 mg; cholestyramine 4 to 16 mg; ezetimibe 10mg (in combination with statin).

Locations
Other Locations
Brazil
OCARA
RECRUITING
Belém
Centro Oncológico de Roraima
RECRUITING
Boa Vista
Instituto de Cardiologia e Transplantes do DF
RECRUITING
Brasília
Universidade do Mato Grosso do Sul
RECRUITING
Campo Grande
Universidade Federal do Mato Grosso
RECRUITING
Cuiabá
Hospital Oto Aldeota
RECRUITING
Fortaleza
Universidade Federal de Goiás
RECRUITING
Goiânia
Universidade Federal do Amapá
RECRUITING
Macapá
Centro de Pesquisas Clínicas Dr. Marco Mota
RECRUITING
Maceió
Universidade Federal do Amazonas
RECRUITING
Manaus
Universidade Estadual de Maringá
RECRUITING
Maringá
Santa Casa de Montes Claros
RECRUITING
Montes Claros
Centro de Estudos e Pesquisas em Moléstias Infecciosas
RECRUITING
Natal
Universidade Federal do Tocantins
RECRUITING
Palmas
Universidade Federal do Vale do São Francisco
RECRUITING
Petrolina
Instituto de Pesquisa e Ensino em Saúde
RECRUITING
Porto Velho
Centro de Pesquisa Silvestre Santé
RECRUITING
Rio Branco
Instituto Nacional de Cardiologia
RECRUITING
Rio De Janeiro
Hospital Ana Nery
RECRUITING
Salvador
Hcor
RECRUITING
São Paulo
InCor
RECRUITING
São Paulo
Instituto Dante Pazzanese de Cardiologia
RECRUITING
São Paulo
Universidade Federal de São Paulo
RECRUITING
São Paulo
Centro de Pesquisa Cardiolima
RECRUITING
Teresina
Contact Information
Primary
Aline Marcadenti, PhD
amarcaden@hcor.com.br
+55 1130536611
Backup
Rachel Helena Machado, MSc
rhelena@hcor.com.br
+55 1130536611
Time Frame
Start Date: 2024-10-23
Estimated Completion Date: 2026-12
Participants
Target number of participants: 300
Treatments
Placebo_comparator: DICA-FH + placebo
Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus placebo of both phytosterol and krill oil during 120 days.
Experimental: DICA-FH + phytosterol
Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of phytosterol and placebo of the krill oil during 120 days.
Experimental: DICA-HF + krill oil
Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of krill oil and placebo of phytosterol during 120 days.
Experimental: DICA-HF + phytosterol + krill oil
Participants allocated into this arm (n= 75) will receive the DICA Br adapted to FH (DICA-FH) plus 2g/day of phytosterol and 2g/day of krill oil during 120 days.
Sponsors
Leads: Hospital do Coracao
Collaborators: University of Sao Paulo

This content was sourced from clinicaltrials.gov

Similar Clinical Trials